CTOs on the Move

Moderna Therapeutics

www.modernatx.com

 
Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.modernatx.com
  • 200 Technology Square
    Cambridge, MA USA 02139
  • Phone: 617.714.6500

Executives

Name Title Contact Details
Brad Miller
Chief Information Officer Profile
Marcello Damiani
Chief Digital Officer Profile
Jerh Collins
Chief Technical Operations and Quality Officer Profile
Adrian Stone
Senior Vice President and Chief Information Security Officer Profile

Funding

Moderna Therapeutics raised $650M on 01/12/2016
Moderna Therapeutics raised $483M on 04/17/2020
Moderna Therapeutics raised $472M on 07/24/2020

Similar Companies

New Horizon Agency Group

New Horizon Agency Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CELLEX BIOSCIENCES

CELLEX BIOSCIENCES is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nanopore Technologies

Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field. Over time, the technology will continue to improve, new form factors of the technology will be introduced and workflows will be further simplified by new preparation techniques or analysis workflows. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment. Oxford Nanopore has developed the worlds first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in >50 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field. Nanopore sensing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The the high-throughput/sample number PromethION is currently being released in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to prepare DNA for addition to a nanopore sequencing device.

Epredia

Improving lives by enhancing precision cancer diagnostics.

Nanogen, Inc.

Nanogen, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.